No Data
No Data
New Analyst Forecast: $TRML Given $50.0 Price Target
Truist Financial Maintains Tourmaline Bio(TRML.US) With Buy Rating
Wedbush Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $43
Tourmaline Bio Price Target Raised to $43.00/Share From $42.00 by Wedbush
Tourmaline Bio Is Maintained at Outperform by Wedbush
Truist Financial Sticks to Their Buy Rating for Tourmaline Bio (TRML)